Friday, October 24, 2014 8:09:42 AM
-Driven by proprietary primary research, not just publicly available data. We conduct over 5,000 interviews annually with company management, customers, partners, and outside experts, including on-site visits and facility inspections in 45 countries
-Based on a deep understanding of technology and markets. Our researchers are not generalist consultants or market researchers, but domain experts (most with advanced degrees in science and engineering), familiar with issues and trends in these technology areas. At the same time, our analysts aren't simply technologists, but are well-versed in assessing business implications of emerging technology
-Factual, detailed, and numerate. We don't indulge in vague generalizations, but support conclusions with specific data, examples, and case studies. Lux Research reports and other deliverables are not merely qualitative, but provide specific numbers – market sizes, figures of merit, price/cost, revenues – to help make decisions
-Bold and opinionated. We do not simply take claims or reports at face value, but apply critical analysis to cut through the hype and get to what is really true. We do not just report data or information, but say what it means – and put a firm stake in the ground in recommending what clients should do.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM